SymBio Pharmaceuticals
About:
SymBio Pharmaceuticals develops therapeutic products for cancer, hematology, and autoimmune diseases.
Website: http://www.symbiopharma.com
Top Investors: Mitsubishi UFJ Capital, Mizuho Capital, SBI Group, DBJ Capital, JAFCO
Description:
SymBio Pharmaceuticals Limited operates as a biopharmaceutical company. It offers Symbenda medicine for treating low-grade non-Hodgkin's lymphoma and chronic lymphatic leukemia in Singapore. The company was founded in 2005 and is headquartered in Tokyo, Japan.
Total Funding Amount:
$746M
Estimated Revenue Range:
Less than $1M
Headquarters Location:
Tokyo, Tokyo, Japan
Founded Date:
2005-03-01
Founders:
Fuminori Yoshida
Number of Employees:
51-100
Last Funding Date:
2016-04-06
IPO Status:
Public
© 2025 bioDAO.ai